On Jun 27, 2018 39.17 % to Target, Merrimack Pharmaceuticals (NASDAQ:MACK) Stock “Neutral” Rating Reaffirmed by Baird.

June 27, 2018 - By Sarah North

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Corporate Logo

Reiterated Merrimack Pharmaceuticals (NASDAQ:MACK) Rating.

After Baird’s $7 target was sent to investors on Tuesday, 26 June, Merrimack Pharmaceuticals (NASDAQ:MACK) suggests 39.17 % upside potential.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Ratings Coverage

In total 3 analysts cover Merrimack Pharmaceuticals (NASDAQ:MACK). “Buy” rating has 0, “Sell” are 1, while 2 are “Hold”. 0 are bullish. 4 are the (NASDAQ:MACK)’s analyst reports since May 8, 2018 according to StockzIntelligence Inc. On Monday, June 25 the firm earned “Underweight” rating by JP Morgan. On Tuesday, June 26 Robert W. Baird maintained Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) with “Neutral” rating. The company rating was maintained by Cowen & Co on Monday, June 25.

MACK is touching $5.03 during the last trading session, after increased 1.51%.Merrimack Pharmaceuticals, Inc. has volume of 176,243 shares. Since June 27, 2017 MACK has declined 62.77% and is downtrending. MACK underperformed by 75.34% the S&P500.

Investors expect Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)’s quarterly earnings on August, 8., RTT reports. Analysts forecast $-1.39 EPS, which is $0.81 up or 36.82 % from 2017’s $-2.2 EPS. 4.51 % negative EPS growth is what Wall Street’s forecasts after $-1.33 reported EPS previous quarter.

Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States.The firm is worth $67.18 million. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1.0.14 is the P/E ratio. The Company’s clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors.

For more Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) news published recently go to: Nasdaq.com, Benzinga.com, Seekingalpha.com, Streetinsider.com or Benzinga.com. The titles are as follows: “Mid-Afternoon Market Update: NASDAQ Down Over 2.5%; Xerium Technologies Shares Spike Higher” published on June 25, 2018, “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” on June 26, 2018, “Merrimack Pharma -31% as pancreatic cancer treatment fails to meet goals” with a publish date: June 25, 2018, “Ex-Akebia employee jailed for night as insider trading trial starts” and the last “Benzinga’s Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading” with publication date: June 27, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: